Allergan to Buy MAP Pharmaceuticals for $958 Million
Allergan, Inc., has agreed to pay nearly $1 billion to
acquire MAP Pharmaceuticals, a biopharmaceutical company
focused on developing and commercializing new
therapies in neurology, the two companies announced in
a news release. The purchase price of $25 a share in cash
is a 60% premium over MAP’s closing price of $1...